Innovative ctDNA Testing Drives Progress in NSCLC Research
The TROPION-Lung12 trial uses a circulating tumor DNA assay to preoperatively screen patients with non–small cell lung cancer for eligibility in post-surgical adjuvant treatment regimens.
Related Articles
An Assortment of Journal Abstracts to Enhance Oncology Care : Oncology Times
An abstract is unavailable.
Navigating a “Sea Change” in Frontline Urothelial Carcinoma Treatment
David H. Aggen, MD, PhD, details the evolving landscape of treating patients with urothelial carcinoma.
Toripalimab Plus Chemo: A First-Line Option for ES-SCLC? – Oncology Nurse Advisor
Study authors said toripalimab plus chemotherapy could be a first-line treatment option, but authors of a related commentary said a global study may be needed…
A Quick Start Guide to Cancer Data Science for Clinical Oncology | CBIIT
Whether you are in the data science field, interested in developing computational solutions for clinical oncology, or a clinical researcher, we’ve curated a list of…
Dr Scandura on the SENTRY-2 Trial of Single-Agent Selinexor in JAK Inhibitor–Naive Myelofibrosis
Joseph M. Scandura, MD, PhD, discusses the phase 2 SENTRY-2 study evaluating single-agent selinexor in JAK inhibitor–naive myelofibrosis.
Functional High-Risk is a Leading Rationale for Early CAR T in Myeloma
Samer A. Al’Hadidi, MD, discusses factors influencing early use of chimeric antigen receptor T-cell therapy in patients with relapsed/refractory multiple myeloma.
Research Aims to Expand RAS Inhibitor Options in Pancreatic Cancer
Brandon G. Smaglo, MD, FACP, discusses ongoing research with novel RAS inhibitors in pancreatic cancer.
Incidence and Characterization of Secondary CNS Lymphoma in 1,972 Patients with DLBCL – A Danish Nationwide Cohort Study
Key Points. The cumulative incidence of SCNSL was 2.6% at two years with death and relapse without CNS involvement as competing risksThe most significant p
Advancing Predictive Biomarkers for Colon Cancer Treatment : Oncology Times
An abstract is unavailable.